Sarepta Exondys 51 and Vyondys 53 sales up 23% in Q3

• Sarepta Therapeutics (NASDAQ:SRPT) Q3 results:
• Revenues: $143.9M (+45.4%); product sales: $121.4M (+22.6%); collaboration revenue: $22.5M (primarily from Roche).
• Net loss: ($196.5M) (-55.6%); loss/share: ($2.50) (-47.1%).
• Quick assets: $1,816,1M (+61.5%).
• Q4 consensus: loss/share of ($1.78) on revenues of $145.3M.
• Data readout on SRP-5051 by year-end.
• U.S. marketing application for Amondys 45 (casimersen) for DMD patients amenable to exon 45 skipping currently under FDA review with an action date of February 25, 2021.
• Dosing to begin this quarter in new 10-subject study evaluating the safety and expression of commercial process material for SRP-9001, its gene transfer therapy for DMD. Preliminary data should be available in early 2021.
• https://www.blogger.com/blog/post/edit/3207539574676545063/5543057765168700814